Ep34: Ron Renaud

Episode Summary

Executive Summary: Ron Renaud traces a career from Dana-Farber and Amgen to Wall Street and back into biotech leadership, showing how a non-scientist CEO can succeed by asking sharp questions, hiring well, and focusing on culture. He explains Translate Bio’s pivot from long non-coding RNA to messenger RNA, the Shire-derived platform, and the company’s lead programs in cystic fibrosis and OTC deficiency.

Main Topics: Early life and scientific curiosity (Priority: 4/5): Renaud grew up in Worcester/Grafton, Massachusetts, intended to become a pediatrician, and entered college as pre-med before switching to psychology after organic chemistry proved decisive. Dana-Farber and first biotech exposure (Priority: 5/5): His post-college work at Dana-Farber placed him in breast cancer clinical research and a lab setting, exposing him to Amgen drugs, patient impact, and translational science. Amgen and learning management from the inside (Priority: 5/5): At Amgen he moved from clinical research to investor relations, learning how executive teams make decisions, how finance and science intersect, and how a finance-first leader like Gordon Binder could guide scientists with simple questions. Wall Street perspective and strategic judgment (Priority: 4/5): As a biotech analyst, Renaud learned to evaluate management, M&A, and the gap between being scientifically right and stock-market right, which later shaped his CEO style. Carex and Identix leadership experience (Priority: 5/5): Returning to operating roles, he became CFO and later CEO at Identix, helped steer a hepatitis C franchise through intense competition, and oversaw the company’s $3.85 billion acquisition by Merck. Translate Bio’s pivot to mRNA (Priority: 5/5): As CEO of Rana Therapeutics, he realized the long non-coding RNA platform would take too long, then acquired Shire’s stealth mRNA platform and rebranded the company as Translate Bio. Cystic fibrosis, delivery, and pipeline strategy (Priority: 5/5): Translate Bio’s lead program aims to deliver CFTR mRNA to the lungs via nebulization and lipid nanoparticles, with follow-on efforts in OTC deficiency, vaccines, and other tissues.

Key Arguments: A non-scientist CEO can lead effectively if he or she deeply understands the science, asks the right questions, and empowers strong teams. Biotech success is fundamentally about people and culture; strategy matters, but a strong culture and low turnover are more durable competitive advantages. Translate Bio’s mRNA platform benefits from a decade-plus head start in solving key problems such as stability, immunogenicity, delivery, and manufacturing. The company’s cystic fibrosis approach is pan-mutational, aiming to treat all CF patients regardless of mutation by replacing missing CFTR protein. mRNA therapy may avoid some limitations of DNA/gene therapy because it only needs to enter the cytoplasm, not the nucleus, and can be titrated more easily. The industry remains broad enough for multiple winners; mRNA, gene therapy, gene editing, and enzyme replacement can all have distinct roles. Patient impact should drive decision-making, with data—not hype—guiding advancement and portfolio choices.

Data Points: Distance from Grafton to Boston: about 45 miles west of Boston - Describing his upbringing in central Massachusetts College graduation year: 1990 - Estimated from the transcript; he graduated from St. Anselm around this time Amgen start year: 1994 - He joined Amgen in the middle/early part of 1994 Identix acquisition value: $3.85 billion - Merck acquired Identix in 2014 Identix acquisition year: 2014 - End of his CEO run at Identix Rana/Translate mRNA platform age: 8 years old in 2016 - He said the Shire mRNA platform had been built for about eight years before acquisition Shire discussions duration: almost half of 2016 - Negotiations to acquire the mRNA platform First company to clinic claim: first messenger RNA to the clinic in a genetic disease - Translate Bio’s cystic fibrosis program Public offering proceeds: about $113 million - He referenced the company’s recent IPO/financing Office integration distance: 11 miles - Cambridge and Lexington offices were geographically close but operationally fragmented Protein expression increase: 200x to 1600x endogenous protein - Preclinical inhaled mRNA results in lungs CF trial design: phase 1/2, single ascending dose then multiple ascending dose - Clinical development plan for MRT-5005 Current/lead CF program name: MRT-5005 - Translate Bio’s inhaled CFTR mRNA candidate Potential OTC filing timing: by the end of this year - He said they hoped to file an IND for OTC deficiency by year-end

Pivotal Quotes: "If you’re a biotech CEO who’s a non-scientist, you had better be fluent in the scientific concepts, know the key questions to ask, and hire good people." — Luke Timmerman: Framing Renaud’s leadership style before the interview "Culture trumps everything." — Ron Renaud: Explaining how he thinks about building durable biotech companies "What I would just say is that we try to live it. We try to focus on it every single day and we try to make sure it just doesn’t become something that is commonplace." — Ron Renaud: On keeping patient focus authentic rather than rhetorical

Implications: The interview shows mRNA’s breadth beyond vaccines and highlights how platform biotech depends on long-term technical persistence, disciplined capital allocation, and strong culture. It also suggests non-scientist CEOs can succeed by translating complex science into rigorous, patient-centered execution.